DEF: Integer Holdings Corporation Announces 2025 Annual Meeting and Proxy Statement

Integer Holdings Corporation invites stockholders to its 2025 Annual Meeting on May 21, 2025, to vote on director elections, auditor ratification, executive compensation, and an amendment to the company's Restated Certificate of Incorporation.

Summary

• Integer Holdings Corporation has announced its 2025 Annual Meeting of Stockholders to be held on May 21, 2025, in Plano, Texas.
• Stockholders of record as of March 24, 2025, are eligible to vote on the election of 10 directors, ratification of Deloitte & Touche LLP as the independent auditor, an advisory vote on executive compensation, and an amendment to the company's Restated Certificate of Incorporation.
• The Board recommends voting for all director nominees, ratifying the auditor appointment, approving executive compensation, and approving the certificate amendment.
• The company's 2024 performance highlights include a 10% increase in sales to $1.717 billion and a 28% increase in operating income to $208 million.
• Adjusted operating income increased 20% to $285 million, and adjusted earnings per share increased 15% to $5.30 per share.
• The company divested Electrochem Solutions Inc. in October 2024 to focus on its medical device CDMO business.
• Integer completed the acquisition of Pulse Technologies in January 2024 and opened a new development and manufacturing center in Galway, Ireland, in September 2024.
• The company's executive compensation program is designed to attract, retain, and motivate executives, linking pay to performance and stockholder interests.
• The compensation program includes base salary, short-term incentives (STI), and long-term incentives (LTI), with a significant portion of executive pay tied to performance goals.
• The Compensation Committee approved short-term incentive payouts based on achievement against targets established early in 2024, and did not use discretion to adjust payout.
• The company maintains a compensation recoupment policy and stock ownership guidelines for executive officers and non-employee directors.
• The Board has determined that all director nominees, except for the CEO, are independent under NYSE standards.
• William B. Summers Jr. will retire from the board of directors after 24 years of service at the conclusion of his term effective with the Annual Meeting.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Integer Holdings, highlighting strong financial performance, strategic acquisitions, and a commitment to corporate governance and ESG matters. The Board's recommendations for voting on the proposals further reinforce a sense of confidence in the company's direction.

Positives

• The company achieved strong financial results in 2024, with significant growth in sales, operating income, and earnings per share.
• The divestiture of Electrochem allows the company to focus on its core medical device CDMO business.
• Strategic acquisitions and facility expansions are expected to drive future growth.
• The executive compensation program is designed to align executive pay with performance and stockholder interests.
• The company maintains strong corporate governance practices, including a compensation recoupment policy and stock ownership guidelines.
• The Board is composed of a majority of independent directors.
• The company is committed to environmental, social, and governance (ESG) matters.

Risks

• The document does not explicitly detail any specific risks, but general business risks associated with the medical device industry, such as regulatory changes, competition, and supply chain disruptions, may apply.

Future Outlook

Integer believes it is positioned to sustainably grow sales high single digit to low double digits for years to come and expects to see significant growth for its associates, customers, stockholders and the communities in which it lives and work.

Management Comments

• Integer is on a Journey to Excellence with a clear strategy to win in the markets we serve and achieve excellence in all that we do.
• We delivered strong results in 2024, and we believe we are positioned to sustainably grow sales high single digit to low double digits for years to come.
• As we continue on our Journey to Excellence, we expect to see significant growth for our associates, our customers, our stockholders and the communities in which we live and work, all while achieving our vision to enhance the lives of patients worldwide by being our customers partner of choice for innovative technologies.

Industry Context

Integer's focus on medical device contract development and manufacturing aligns with the growing trend of outsourcing in the medical device industry. The company's strategic acquisitions and expansions position it to capitalize on the increasing demand for specialized manufacturing capabilities in high-growth markets.

Comparison to Industry Standards

• Integer competes with other medical device CDMOs such as Medtronic, Stryker, and Boston Scientific, although these companies also have significant internal manufacturing capabilities.
• The company's financial performance is assessed against its peer group, which includes companies like Avanos Medical, ICU Medical, and Teleflex Incorporated.
• Integer's executive compensation practices are benchmarked against these peer companies to ensure competitiveness.
• The company's commitment to ESG matters aligns with increasing investor expectations for corporate social responsibility.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The company's performance and governance practices are designed to enhance shareholder value.
• Employees: The company is committed to creating an inclusive work environment and providing opportunities for growth and development.
• Customers: The company aims to be the partner of choice for innovative technologies, enhancing the lives of patients worldwide.
• Communities: The company is committed to conducting business in a socially and environmentally responsible manner.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting on May 21, 2025.
• The Board will consider the results of the advisory vote on executive compensation when making future decisions.
• The company will continue to execute its strategic plan and pursue growth opportunities.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Integer Holdings, Executive Compensation, Board of Directors, Corporate Governance, Financial Performance, Director Election, Auditor Ratification, Officer Exculpation, Medical Device, CDMO, ESG